Immunotherapy plus chemoradiotherapy for limited stage small cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests an immunotherapy drug (envafolimab) given together with standard chemotherapy and radiation for limited-stage small cell lung cancer. It aims to see if adding this treatment helps control the cancer better than standard treatment alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have small cell lung cancer that is limited to one side of your chest and can be treated with a single radiation field.
- You have not had any prior treatment for this cancer, except for two cycles of standard chemotherapy (etoposide plus cisplatin or carboplatin).
- You are between 18 and 75 years old and weigh more than 30 kilograms.
- You are in good overall health (able to carry out daily activities without significant difficulty), and your blood tests show adequate liver, kidney, and bone marrow function.
- You do not have serious other medical conditions, ongoing infections, or a history of prior immunotherapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of treatments for advanced non-small cell lung cancer (NSCLC) that has not been treated before. It combines a type of immunotherapy (envafolimab) with a drug that may slow blood vessel growth (endostar) and a special type of radiation therapy (SRT). This may help shrink tumors and control the cancer for a longer time.
This trial combines radiation therapy with chemotherapy and an immunotherapy drug to treat limited-stage small cell lung cancer. The goal is to see if this approach helps people live longer and delays the cancer from coming back.
This trial tests a new drug (adebrelimab) combined with standard chemotherapy and radiation for limited-stage small cell lung cancer. After the initial treatment, the drug is continued to help keep the cancer from coming back.
This trial tests a combination of an immunotherapy drug (tislelizumab) with standard chemotherapy (and sometimes radiation) for people with small cell lung cancer that has spread to only a few spots in the body. The goal is to see if adding immunotherapy helps control the cancer better than chemotherapy alone.
This trial tests giving standard chemotherapy and radiation together with two types of immunotherapy (which helps your immune system fight cancer) for limited-stage small cell lung cancer. The goal is to see if adding these immune treatments improves outcomes compared to standard care.
This trial tests a combination of immunotherapy (adebrelimab), chemotherapy, and targeted radiation (SBRT) before surgery for people with limited-stage small cell lung cancer. The goal is to see if this approach can shrink tumors and improve outcomes before the main treatment.
Hear when a new Lung Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.